Market Overview

UPDATE: Morgan Stanley Cuts PT to $27 on Sagent Pharmaceuticals; Progress Amid Soft Q1

Share:
Related SGNT
ETFs For The Next Pharma Takeover Candidates
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Morgan Stanley lowers its price from $28 to $27 on Overweight-rated Sagent Pharmaceuticals (NASDAQ: SGNT) following Q1 results coming in below expectations.

Morgan Stanley notes, "1Q12 revenue was below expectations, but positive pipeline and contracting updates support our long-term thesis of a broadening and profitable base driving revenue growth and margin leverage in an injectables market with attractive fundamentals."

SGNT closed at $16.88 on Friday.

Latest Ratings for SGNT

DateFirmActionFromTo
Jun 2015Raymond JamesInitiates Coverage onStrong Buy
Apr 2015Deutsche BankInitiates Coverage onBuy
Dec 2014JefferiesMaintainsHold

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (SGNT)

Get Benzinga's Newsletters